Metabolism-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition worldwide and affects nearly 30% of the global population. While traditionally associated with metabolic risk factors, such as obesity and insulin resistance, increasing attention is being directed toward socioeconomic and environmental determinants that contribute to disparities in MASLD prevalence and outcomes. Low-income populations often experience higher rates of MASLD owing to limited access to healthcare, poor diet quality, and reduced opportunities for physical activity. Conversely, high-income countries are witnessing a paradoxical rise in MASLD cases, driven by sedentary lifestyles and excessive consumption of ultra-processed foods. This review examined the effects of socioeconomic status, education, healthcare access, and environmental exposure on the epidemiology of MASLD. The findings revealed that individuals from lower socioeconomic backgrounds and migrant populations experience a disproportionately higher burden of MASLD due to systemic healthcare barriers, dietary transitions, and occupational exposure. Children and adolescents face increasing susceptibility owing to rising obesity rates, and geographic disparities highlight Europe as the most affected region, followed by Asia and North America. Given the growing public health impact of MASLD, addressing both socioeconomic and environmental determinants is essential. Future efforts should prioritize policy-driven interventions, including equitable healthcare access, lifestyle modifications, and research into novel therapeutic approaches to mitigate the disease burden and improve patient outcomes.

Citations

• Rising burden of steatotic liver disease in women of childbearing age and projections to 2035
  Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang
  JHEP Reports.2026; 8(1): 101646.     CrossRef
• Atraric Acid Mitigates Mitochondrial Dysfunction and Inflammation via AMPKα–PGC-1α Signaling in Metabolic-Associated Fatty Liver Disease
  Yannan Xiang, Zhihao Ma, Tianyue Guan, Hongyu Huang, Xinran Li, Zihan Xu, Panpan Zhao, Lei Wang
  Antioxidants & Redox Signaling.2026; 44(7-9): 332.     CrossRef
• Vitamin D and the metabolic-associated steatotic liver disease—type 2 diabetes axis: a scoping-narrative review of global evidence and emerging perspectives for Sub-Saharan Africa
  Bruno Basil
  Frontiers in Epidemiology.2026;[Epub]     CrossRef
• MASLD In Children - A Distinct Phenotype?
  Pervej Alom Barbhuiya, Manash Pratim Pathak
  Current Obesity Reports.2026;[Epub]     CrossRef
• GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
  Klaudia Nowak, Krzysztof Łupina, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura
  Current Pharmacology Reports.2026;[Epub]     CrossRef
• Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis
  Yusuf Yilmaz
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
  James Kim, Paolo Raggi, Anne‐Marie Carreau, Sean Wharton, Alice Y. Y. Cheng, Mark G. Swain
  Diabetes, Obesity and Metabolism.2025; 27(12): 6831.     CrossRef
• The association between neighborhood context, allostatic load, and metabolic dysfunction-associated steatosis liver disease in Mexican-origin farmworkers along the Southern Arizona US/Mexico border
  A. Maldonado, E. Torres, M. Flores, M. Rodriguez, E.A. Villavicencio, R. Torres, I. Castro, F. Torres, J.C. Loya, N. Alkhouri, S. Carvajal, Garcia
  SSM - Population Health.2025; 32: 101862.     CrossRef
• Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
  Ralf Weiskirchen, Amedeo Lonardo
  International Journal of Molecular Sciences.2025; 26(19): 9594.     CrossRef
• Enhancing MAFLD Care: Efficacy of a Multidisciplinary Community Intervention on Self-Management and Hepatic Outcomes
  Huan-Jing Cai, Hai-Lun Liang, Lei-Yu Shi, Yi-Hui Rong, Jing Li, Yan Zhang, Rui-Fang Ma
  INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2025;[Epub]     CrossRef
• From steatosis to cirrhosis: the role of obesity in the progression of liver disease
  Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura
  Journal of Diabetes & Metabolic Disorders.2025;[Epub]     CrossRef
• Implementation of noninvasive liver disease screening tools in primary care
  Klaudia Nowak, Adrian Nowak, Aleksandra Jabłońska, Anna Potaczek, Julia Salacha, Natalia Dardzińska, Jakub Janczura
  Korean Journal of Family Medicine.2025; 46(6): 381.     CrossRef